Clinical Report: Link Between Serum Levels of Coiled-Coil Domain Containing Protein 11 and Coronary Artery Disease
Overview
This study investigates the association between serum levels of coiled-coil domain containing protein 11 (CCDC11) and coronary artery disease (CAD). Elevated CCDC11 levels were found to correlate with the presence and severity of CAD, suggesting its potential as a novel biomarker.
Background
Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide, primarily driven by atherosclerosis and associated inflammatory processes. Identifying reliable biomarkers for CAD can enhance risk stratification and guide therapeutic interventions. The role of CCDC11 in inflammation and its potential link to CAD necessitate further exploration.
Data Highlights
Group
Median CCDC11 (ng/mL)
P-value
CAD
20.4
< 0.001
Controls
13.8
Key Findings
Median serum CCDC11 levels were significantly higher in CAD patients compared to controls (20.4 vs. 13.8 ng/mL, P < 0.001).
CCDC11 levels positively correlated with the number of affected coronary vessels (P for trend < 0.001).
Logistic regression confirmed CCDC11 as an independent predictor of CAD.
ROC analysis showed an AUC of 0.71 for CCDC11 in CAD discrimination, outperforming CRP (0.56, P < 0.01).
An optimal CCDC11 cutoff value of 19.37 ng/mL was identified, with a sensitivity of 53.4% and specificity of 91.6% for CAD.
Clinical Implications
The findings suggest that CCDC11 may serve as a valuable biomarker for assessing CAD risk and severity. Clinicians should consider incorporating CCDC11 measurement into the diagnostic workup for patients with suspected CAD to enhance risk stratification.
Conclusion
Elevated serum CCDC11 levels are associated with both the presence and severity of CAD, indicating its potential utility as a biomarker in clinical practice.
